Friday, December 11, 2015
WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, and PRA Health Sciences, a global clinical CRO, have announced a restructuring of their relationship for the delivery of clinical trial management services in China, Macau and Hong Kong.
Syncona, an independent subsidiary of the Wellcome Trust, and UCL Business have announced the creation of biopharmaceutical company Freeline Therapeutics to develop and commercialize gene therapies for bleeding and other debilitating disorders.
Laboratory Corporation of America Holdings (LabCorp), a Burlington, N.C.-based healthcare diagnostics company, has entered into a definitive agreement to acquire substantially all of the operating assets of Pathology Inc., including patient service centers, used to conduct Pathology’s medical testing and services business.
Ajinomoto Althea, a leading provider of biopharmaceutical contract development and manufacturing services, is expanding its existing biological drug product manufacturing operations to include highly active materials such as antibody drug conjugates (ADCs). [Read More]
Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), today announced the completion of two successful phase I trials with its lead compound TW001, a more patient-friendly oral formulation of the Japanese stroke and ALS therapy edaravone. [Read More]
Baxalta, a global biopharmaceutical provider dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has announced that the FDA has approved VONVENDI, for treatment of von Willebrand disease (VWD).
CSL Behring, a global biotherapeutics company, has announced its latest geographic expansion to provide more patients with greater access to treatment by opening operations in Russia.
Tokyo-based Daiichi Sankyo has decided to close its Martinsried, Germany-based research subsidiary, U3 Pharma.
Bristol-Myers Squibb and the department of chemistry at Princeton University have launched a new research collaboration that includes the establishment of the Center for Molecular Synthesis (BMS-CMS).